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proportion of HPV-related cancers remains to be established site by site and further 
research is needed to assess outpatient and indirect costs linked to these cancers.
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OBJECTIVES: This incidence-based cost-of-illness analysis aims to quantify the costs 
associated with female breast cancer in Flanders for the year prior to diagnosis and 
for each of the ﬁve years following diagnosis. METHODS: A bottom-up analysis from 
the societal perspective included direct health care costs and indirect costs of produc-
tivity loss due to morbidity and premature mortality. A retrospective case-control 
study design compared total costs of breast cancer patients with costs of an equivalent 
standardised population with a view to calculating the additional costs that can be 
attributed to breast cancer. The sample was made up of women who had undergone 
surgical treatment for breast cancer and who were afﬁliated with the Christian Health 
Insurance Funds. Resource utilisation data were derived from national publications, 
the Christian Health Insurance Funds and statistical institutes. RESULTS: The sample 
consisted of 20,439 breast cancer patients. Total average costs of breast cancer 
amounted to a107,456 per patient over 6 years. Total costs consisted of productivity 
loss costs (89% of costs) and health care costs (11% of costs). Health care costs did 
not vary with age at diagnosis. Health care costs of breast cancer patients converged 
with those of the general population at ﬁve years following diagnosis. Patients with 
advanced breast cancer stadia had higher health care costs. CONCLUSIONS: To 
reduce costs associated with breast cancer, attention needs to be focused on decreasing 
the productivity loss from breast cancer. The implementation of new techniques to 
prevent, diagnose, and treat breast cancer not only impact direct health care costs, 
but may also inﬂuence indirect costs of productivity loss.
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OBJECTIVES: In Brazil, 140 million citizens (^80% of the population) depend on the 
public health care system. Advanced gastric cancer (AGC) is the second most frequent 
cause of death in Brazil: 10,645 per year. This disease appears among the most costly 
cancers to treat. Objective was to identify the medical resource usage (MRU) to treat 
AGC and estimate the associated costs in the public health care sector in Brazil. 
METHODS: A questionnaire was developed to identify the medical resource usage 
(MRU) of managing AGC in the public health care system. The questionnaire was 
applied to 20 oncologists and 20 nurses in a structured interview. MRU data were 
extracted according to the following stages: 1) diagnosis and staging; 2) 1st line treat-
ment, 3) 2nd line treatment; 4) best supportive care (BSC); and 5) terminal care. Then, 
modiﬁed Delphi panels were conducted in the 5 largest cities of Brazil to reach a con-
sensus on the base-case value and on the possible ranges of each resource used. 
Financial values were translated into USD based on the exchange rate of R$2.40  
US$1.0. RESULTS: The mostly used diagnostic procedures were upper digestive 
endoscopy, abdominal computed axial tomography (CAT) and thoracic radiography. 
For 1st line treatment, 5FU-based chemo was the ﬁrst choice of 50% of the oncologists 
interviewed, either given in combination with cisplatin (22%), etoposide (17%) or 
cisplatin plus doxorubicin (11%). Most commonly used resources in BSC/terminal 
care were blood analysis and anti-algic radiation. The mean cost per patient were: 
diagnostic and staging: R$451 (US$188); 1st line treatment: R$4565 (US$1902); 2nd 
line treatment: R$2740 (US$1142); BSC: R$883 (US$368); and terminal care: R$416 
(US$173). The total mean cost per patient were therefore R$9056 (US$3773) of which 
chemotherapy drugs represented 37%. CONCLUSIONS: Findings suggest that the 
total mean cost of treating AGC per patient in the public sector in Brazil is R$9056 
(US$3773).
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OBJECTIVES: Gastric cancer is the second most frequent cause of cancer death 
worldwide. Approximately 22,000 new cases are expected in Brazil annually. Our aim 
was to estimate the cost per disease stage of advanced gastric cancer in Brazil in the 
private health care sector. METHODS: A questionnaire was developed to identify the 
medical resource usage (MRU) of managing gastric cancer in the private health care 
system. The questionnaire was applied in a structured interview to 40 experts (20 
oncologists and 20 nurses) who represented different Brazilian regions. MRU data 
were extracted according to the following stages: 1) diagnosis and staging; 2) 1st line 
treatment; 3) 2nd line treatment; 4) best supportive care (BSC), and v) terminal care. 
Later, a modiﬁed Delphi panel was conducted to reach a consensus on the base-case 
value and on possible ranges for each resource identiﬁed. A micro-costing technique 
was then applied to calculate costs. Financial values were translated into USD based 
on the exchange rate of R$2.40  US$1.0. RESULTS: The most used diagnostic pro-
cedures were upper digestive endoscopy, abdominal computed axial tomography 
(CAT) and thoracic radiography. 5FU/capecitabine-based chemo was the oncologists’ 
ﬁrst choice for both 1st and 2nd line treatment (48% and 42%, respectively). Most 
commonly used resources in the BSC/ terminal care stages were medical visits and 
blood analysis. The mean cost per patient were: diagnostic and staging: R$1,283 (US$ 
535); 1st line treatment: R$ 0.502 (US$12,710); 2nd line treatment: R$ 6,406 
(US$2,670); BSC; R$6,833 (US$2,847); and terminal care: R$743 (US$310). The total 
mean cost per patient were R$45,768 (US$19,070), of which chemotherapy drugs 
represented 66%. CONCLUSIONS: The ﬁndings indicate that the most expensive 
stage in treating advanced gastric cancer in the private sector in Brazil is the 1st line 
treatment. Further studies are recommended to explore the results.
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OBJECTIVES: To examine the patient characteristics, comorbidities, and medication 
usage of subjects diagnosed with mGC. METHODS: Subjects in the Marketscan 
Commercial Claims and Encounter Database (July 1, 2003–June 30, 2008) were 
included for analysis if they received a diagnosis of mestastasis based on ICD-9 codes 
on or after the ﬁrst occurrence of GC, had no claims for other secondary metastases 
in the 6 months prior to the initial mGC claim, and had continuous insurance coverage 
from 6 months prior through at least one month post the initial diagnoses of mGC. 
Health care costs and resource utilization (HRU) are described from the date of initial 
mGC diagnosis through end of data collection due to patient drop out or end of the 
data collection period (e.g. post-period). Study data are shown as summary (or descrip-
tive) statistics. RESULTS: A total of 2058 subjects with mGC were included in the 
analysis. At mGC diagnosis, the median age was 58 years (25th /75th percentile: 31 
and 62 years respectively) and 60% were male. The mean length of follow-up after 
mGC was 2.6 years (SD: 1.3 years). The most common comorbidities at the time of 
mGC diagnosis were cardiovascular disease (48%), hypertension (29%), and diabetes 
(16%). Sixty-ﬁve percent of mGC subjects received outpatient chemotherapy in the 
post-period. Mean monthly medical costs were $5080 in the post-period, which con-
sisted of 46% inpatient costs, 40% outpatient costs, and 14% outpatient chemother-
apy costs. CONCLUSIONS: One-third of mGC patients were not treated with 
outpatient oncolytics. Outpatient chemotherapy costs constituted a small portion of 
the total cost of mGC.
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OBJECTIVES: Sunitinib and sorafenib, the multikinase inhibitors, launched into the 
Czech market in the middle of 2006 as a second-line treatment of metastatic renal cell 
carcinoma (mRCC) and were not yet economically evaluated in real clinical practice. 
The aim was to assess direct medical costs in mRCC patients treated in comprehensive 
cancer centre from a health care payer perspective. METHODS: Between May 2006 
and May 2009 31 mRCC patients were treated with sorafenib and/or sunitinib after 
previous cytokine therapy failure (mean age 52 years; 23 men). The progression of 
disease and costs (including concomitant medication, examination, check-ups, hospi-
talization) were assessed each two-months of therapy. Cost of cycle to progression, 
cost of cycle after progression and the structure of costs were determined. (1a  
26.8CZK) RESULTS: Seventeen patients started therapy with sunitinib, 8 of which         
were converted to sorafenib after progression. 3 patients ﬁnished sunitinib therapy 
due to adverse events (AE). Fourteen patients started with sorafenib therapy, 2 of 
which were converted to sunitinib due to AE, other 2 patients were converted to 
sunitinib after progression. The main AE were skin toxicity, oedema, arthralgia and 
other pain. The dose was reduced in 10 patients due to AE. Median number of two-
month progression free cycles was 4; mean cost of one cycle was a7546. Cost of 
medication formed 95.4% (sunitinibsorafenib 94.3%), investigations and check-ups 
4.42% and hospitalizations 0.18% of total costs. Median two-month cycles after 
progression was 2 with mean cost a4840. Sunitinib and sorafenib formed 90.5%, 
investigations and check-ups 6.2%; and hospitalizations 0.8% of total costs; 9 patients 
died. CONCLUSIONS: The analysis of direct medical costs in patients with mRCC 
proved high costs concerned with multikinase inhibitors´ therapy. Since data on the 
economic burden of oncology treatment in the Czech Republic are limited it is essential 
to start with cost-of-illness studies to enable pharmacoeconomic analyses for drug 
reimbursement.
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OBJECTIVES: Renal cell carcinoma (RCC) accounts for three peercent deaths in 
Finland. However, information on treatment modalities and the cost of treatment in 
different hospitals is scarce. The aim of the study was to clarify the current situation 
